A Phase 2 interventional study of eltrombopag in Immune Thrombocytopenic Purpura (ITP), sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 23rd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis: 4 open now, 7 under way, 2 of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 2, and was the 4th registered.
Novartis’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2006.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 17 in Purpura, Thrombocytopenic, Idiopathic:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.
Protocol Amendment 01 added a follow-up period of 12 months for patients with sustained response off treatment at month 12 to obtain further data on response duration.
The starting dose was eltrombopag 50 mg daily (25 mg daily for Asian patients and 12.5 mg daily for Japanese patients in Japan). The starting dose for this study was consistent with the dosing guidelines approved for eltrombopag use in ITP. An increase of eltrombopag dose up to 75 mg was allowed for patients who did not respond to standard-dosage treatment and to reduce the risk of bleeding. The rationale for this increased dose was to use the minimal efficacious dosage of eltrombopag in order to achieve a platelet count ≥ 100×10\^9/L and maintain it around 100×10\^9/L (no counts below 70×10\^9/L) for 2 months in order to allow patients to start the eltrombopag tapering and withdrawal process.
Patients who reached a platelet count of >= 100 × 10\^9/L and maintained counts around 100×10\^9/L for 2 months with no platelet count \< 70 × 10\^9/L were eligible for tapering-off and treatment discontinuation, which occurred via 25 mg reduction every 2 weeks up to 25 mg on alternate days for 2 weeks until treatment discontinuation.
Patients who successfully discontinue eltrombopag and maintained platelet count >= 30 × 10\^9/L in the absence of bleeding or use of rescue therapy were followed to month 12. If a relapse (defined as platelet count \<30 × 10\^9/L) occurred during the 12-month treatment period, they were offered a new course of eltrombopag treatment within this timeframe at the appropriate starting dose. If a patient relapsed in the post 12-month follow-up period, no further attempts for tapering and achieving sustained response off treatment were made.
The taper-off scheme followed recommendations within the current established dosing regimen for when to consider dose adjustment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of \>=100×10\^9/L (CR), after 1st line steroids had failed.
Drug: eltrombopag
12.5, 25, 50 and 75 mg tablets for oral use once daily
Also known as: ETB115
Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.
Time frame: Month 12
Median Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.
Time frame: From last dose of eltrombopag to month 12
Estimated Median Duration of Sustained Response Off Treatment (SRoT) for Participants With Sustained Response Off Treatment at Month 12 and Who Enter 12 Months Follow-up Period
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy. Patients with SRoT until month 12 who entered follow-up and did not relapse by cut-off date/Month 24 were censored at the earliest of discontinuation date/death date/Month 24 platelet assessment date/cutoff date. Patients with SRoT until Month 12 patients who did not enter or do not yet have data in follow-up phase are censored at their Month 12 platelet assessment date.
Time frame: From last dose of eltrombopag to relapse, assessed up to month 24
Estimated Median Duration of Sustained Response Off Treatment (SRot) for All Patients
Patients who tapered and discontinued successfully, or did not relapse/die by cutoff date /month 24 were censored at the earliest of discontinuation date/death date/month 24 platelet assessment date/cutoff date.
Time frame: From last dose of eltrombopag to month 24
Percentage of Participants With Sustained Response Off Treatment Until Month 24
Sustained response off treatment is defined as reach platelet count ≥ 100×10\^9/L (complete response \[CR\]) and then maintain platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L) AND then taper off the drug until treatment discontinuation while, maintain platelet count ≥ 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy
Time frame: Month 15, 18, 21 and 24
Percentage of Participants With Early Response Within First Month
Early response is defined as reaching a platelet count \>= 50×10\^9/L at least once within the first month (month 1) without bleeding events and no rescue therapy.
Time frame: By 1 month
Percentage of Participants With Recovery Response in Case of Loss of Response During or After Tapering of Eltrombopag Until Month 24
Recovery response is defined as platelet count \>=30×10\^9/L after eltrombopag is re-introduced, in case of loss of response (\< 30×10\^9/L and/or bleeding event) without bleeding events and no rescue therapy.
Time frame: Up to month 24
Relative Change From Baseline in Platelet Count Over Time
Relative change (%) is the absolute change divided by the platelet counts at baseline and multiplied by 100.
Time frame: Baseline, month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Percentage of Participants Who Maintain Platelet Counts Level Within 12 Months and Every 3 Months Until Month 24
Platelet counts level is defined as having platelet counts \>=30×10\^9/L without bleeding events and no rescue therapy.
Time frame: From first time of reaching the level to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionaire
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities over the past 7 days. FACIT-fatigue is scored using a 4-point Likert scale. Items are scored as follows: 4 = Not At All; 3 = A Little Bit; 2 = Somewhat; 1 = Quite A Bit; 0 = Very Much, EXCEPT items #7 and #8 which are reversed scored. Score range from 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life (less fatigue).
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Functional Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) Questionnaire
FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0-24, with higher scores representing better HRQoL
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Bodily Pain (BP) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: General Health (GH) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Health (MH) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Functioning (PF) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Emotional (RE) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Physical (RP) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Social Functioning (SF) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Vitality (VT) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Component Summary (PCS) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Component Summary (MCS) Score
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Percentage of Participants With Worst Post-baseline Value in Functional Assessment of Cancer Therapy-G (GP5)
The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.
Time frame: Baseline to end of treatment visit, assessed up to 12 months for non-responders and up to 24 months for responders
Overall Change of Treatment Satisfaction Using Treatment Satisfaction Questionnaire (TSQM-9)
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
Time frame: Baseline to month 12 (End of Treatment Visit for non-responders) and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
This study was conducted in 32 investigative sites in 15 countries:1 (Austria), 3 (Brazil), 2 (Chile), 2 (France), 2 (Greece), 2 (Italy), 1 (Japan), 2 (Mexico), 1 (Oman), 2 (Russia), 7 (Spain), 1 (Switzerland), 3 (Turkey), 1 (UK), 2 (USA).
| Milestone | Eltrombopag |
|---|---|
| Started | 105 |
| Completed | 63 |
| Not completed | 42 |
| Withdrew: Lack of efficacy | 10 |
| Withdrew: Physician decision (patient non-compliant) | 1 |
| Withdrew: Adverse event | 10 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Patient decision (patient changed her address) | 1 |
| Withdrew: Patient decision (personal reasons) | 1 |
| Withdrew: New therapy for study indication | 6 |
| Withdrew: Death | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Protocol violation | 1 |
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.
| Percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months | 30.5 (21.9 to 40.2) |
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.
| Weeks | Eltrombopag |
|---|---|
| Median Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment | 33.3 (4 to 51) |
Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy. Patients with SRoT until month 12 who entered follow-up and did not relapse by cut-off date/Month 24 were censored at the earliest of discontinuation date/death date/Month 24 platelet assessment date/cutoff date. Patients with SRoT until Month 12 patients who did not enter or do not yet have data in follow-up phase are censored at their Month 12 platelet assessment date.
No measurements were reported for this outcome.
Patients who tapered and discontinued successfully, or did not relapse/die by cutoff date /month 24 were censored at the earliest of discontinuation date/death date/month 24 platelet assessment date/cutoff date.
No measurements were reported for this outcome.
Sustained response off treatment is defined as reach platelet count ≥ 100×10\^9/L (complete response \[CR\]) and then maintain platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L) AND then taper off the drug until treatment discontinuation while, maintain platelet count ≥ 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy
| Participants | Eltrombopag |
|---|---|
| Month 15 | 21 |
| Month 18 | 18 |
| Month 21 | 14 |
| Month 24 | 15 |
Early response is defined as reaching a platelet count \>= 50×10\^9/L at least once within the first month (month 1) without bleeding events and no rescue therapy.
| Percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants With Early Response Within First Month | 76.2 (66.9 to 84.0) |
Recovery response is defined as platelet count \>=30×10\^9/L after eltrombopag is re-introduced, in case of loss of response (\< 30×10\^9/L and/or bleeding event) without bleeding events and no rescue therapy.
| Percentage of participants | Eltrombopag |
|---|---|
| Participants with loss of response | 11.4 (6.0 to 19.1) |
| Participants with recovery response | 6.7 (2.7 to 13.3) |
Relative change (%) is the absolute change divided by the platelet counts at baseline and multiplied by 100.
| Percentage of change | Eltrombopag |
|---|---|
| 3 Months | 1384.29 ± 3383.702 |
| 6 Months | 1313.10 ± 3459.616 |
| 9 Months | 1396.68 ± 3238.680 |
| 12 Months | 1464.95 ± 3509.964 |
| 15 Months | 1622.19 ± 3712.156 |
| 18 Months | 1664.90 ± 3718.191 |
| 21 Months | 2527.20 ± 5098.612 |
| 24 Months | 1691.68 ± 3611.977 |
| end of treatment visit | 1213.91 ± 2952.719 |
Platelet counts level is defined as having platelet counts \>=30×10\^9/L without bleeding events and no rescue therapy.
| Percentage of participants | Eltrombopag |
|---|---|
| maintain platelet counts level from the first time of reaching that level to month 3 | 49.5 (39.6 to 59.5) |
| maintain platelet counts level from the first time of reaching that level to month 6 | 38.1 (28.8 to 48.1) |
| maintain platelet counts level from the first time of reaching that level to month 9 | 28.6 (20.2 to 38.2) |
| maintain platelet counts level from the first time of reaching that level to month 12 | 28.6 (20.2 to 38.2) |
| maintain platelet counts level from the first time of reaching that level to month 15 | 20.0 (12.8 to 28.9) |
| maintain platelet counts level from the first time of reaching that level to month 18 | 17.1 (10.5 to 25.7) |
| maintain platelet counts level from the first time of reaching that level to month 21 | 13.3 (7.5 to 21.4) |
| maintain platelet counts level from the first time of reaching that level to month 24 | 14.3 (8.2 to 22.5) |
| maintain platelet counts level from the first time of reaching that level to end of treatment visit | 31.4 (22.7 to 41.2) |
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities over the past 7 days. FACIT-fatigue is scored using a 4-point Likert scale. Items are scored as follows: 4 = Not At All; 3 = A Little Bit; 2 = Somewhat; 1 = Quite A Bit; 0 = Very Much, EXCEPT items #7 and #8 which are reversed scored. Score range from 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life (less fatigue).
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 5.42 ± 9.700 |
| 6 Months | 6.15 ± 8.779 |
| 9 Months | 6.89 ± 9.291 |
| 12 Months | 7.90 ± 9.064 |
| 15 Months | 7.12 ± 11.720 |
| 18 Months | 8.87 ± 11.644 |
| 21 Months | 8.80 ± 11.112 |
| 24 Months | 8.69 ± 10.635 |
| end of treatment visit | 5.40 ± 10.116 |
FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0-24, with higher scores representing better HRQoL
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 3.80 ± 5.130 |
| 6 Months | 4.35 ± 6.312 |
| 9 Months | 5.60 ± 6.114 |
| 12 Months | 5.62 ± 6.505 |
| 15 Months | 5.44 ± 8.949 |
| 18 Months | 7.04 ± 7.654 |
| 21 Months | 7.32 ± 7.351 |
| 24 Months | 7.08 ± 7.048 |
| end of treatment visit | 4.15 ± 6.631 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 7.55 ± 24.199 |
| 6 Months | 2.75 ± 24.636 |
| 9 Months | 3.82 ± 21.507 |
| 12 Months | 7.53 ± 25.547 |
| 15 Months | 1.96 ± 36.697 |
| 18 Months | 13.61 ± 26.662 |
| 21 Months | 3.00 ± 20.967 |
| 24 Months | 9.27 ± 29.090 |
| end of treatment visit | 5.19 ± 29.460 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 4.12 ± 18.894 |
| 6 Months | 5.39 ± 20.646 |
| 9 Months | 7.40 ± 17.990 |
| 12 Months | 7.62 ± 18.420 |
| 15 Months | 11.17 ± 20.470 |
| 18 Months | 14.78 ± 26.801 |
| 21 Months | 14.36 ± 25.541 |
| 24 Months | 13.92 ± 19.577 |
| end of treatment visit | 3.80 ± 18.122 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 6.74 ± 15.775 |
| 6 Months | 6.97 ± 18.149 |
| 9 Months | 9.78 ± 15.074 |
| 12 Months | 10.26 ± 16.125 |
| 15 Months | 7.08 ± 22.259 |
| 18 Months | 15.22 ± 22.334 |
| 21 Months | 14.32 ± 20.948 |
| 24 Months | 12.50 ± 17.103 |
| end of treatment visit | 6.82 ± 17.058 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 8.48 ± 23.842 |
| 6 Months | 10.90 ± 26.069 |
| 9 Months | 12.67 ± 28.074 |
| 12 Months | 14.31 ± 28.767 |
| 15 Months | 11.87 ± 37.469 |
| 18 Months | 19.35 ± 33.449 |
| 21 Months | 24.09 ± 31.983 |
| 24 Months | 16.54 ± 35.882 |
| end of treatment visit | 9.00 ± 29.376 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 4.42 ± 22.371 |
| 6 Months | 6.15 ± 23.270 |
| 9 Months | 8.89 ± 22.361 |
| 12 Months | 10.20 ± 23.260 |
| 15 Months | 4.86 ± 27.022 |
| 18 Months | 13.04 ± 26.211 |
| 21 Months | 16.29 ± 25.520 |
| 24 Months | 16.03 ± 20.128 |
| end of treatment visit | 7.25 ± 22.078 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 13.26 ± 22.958 |
| 6 Months | 9.43 ± 27.066 |
| 9 Months | 17.36 ± 24.165 |
| 12 Months | 19.94 ± 29.232 |
| 15 Months | 15.89 ± 37.454 |
| 18 Months | 22.55 ± 32.680 |
| 21 Months | 27.27 ± 33.604 |
| 24 Months | 29.81 ± 32.849 |
| end of treatment visit | 15.88 ± 33.332 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 6.06 ± 24.143 |
| 6 Months | 7.17 ± 26.951 |
| 9 Months | 10.00 ± 22.863 |
| 12 Months | 16.38 ± 26.408 |
| 15 Months | 14.58 ± 30.986 |
| 18 Months | 26.63 ± 24.514 |
| 21 Months | 20.45 ± 26.318 |
| 24 Months | 25.96 ± 22.617 |
| end of treatment visit | 11.18 ± 26.236 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 7.48 ± 18.418 |
| 6 Months | 6.45 ± 20.696 |
| 9 Months | 12.78 ± 20.982 |
| 12 Months | 14.33 ± 22.398 |
| 15 Months | 8.33 ± 26.237 |
| 18 Months | 12.23 ± 27.918 |
| 21 Months | 17.33 ± 26.087 |
| 24 Months | 11.06 ± 24.705 |
| end of treatment visit | 8.97 ± 22.503 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 3.46 ± 7.445 |
| 6 Months | 2.72 ± 8.165 |
| 9 Months | 3.92 ± 7.608 |
| 12 Months | 4.85 ± 8.946 |
| 15 Months | 4.37 ± 11.754 |
| 18 Months | 6.77 ± 9.950 |
| 21 Months | 6.65 ± 8.017 |
| 24 Months | 6.63 ± 9.627 |
| end of treatment visit | 3.30 ± 9.728 |
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.
| Unit on a scale | Eltrombopag |
|---|---|
| 3 Months | 2.34 ± 8.443 |
| 6 Months | 2.85 ± 9.451 |
| 9 Months | 4.52 ± 7.815 |
| 12 Months | 5.33 ± 8.719 |
| 15 Months | 3.28 ± 11.083 |
| 18 Months | 7.12 ± 11.312 |
| 21 Months | 7.18 ± 11.143 |
| 24 Months | 6.87 ± 9.081 |
| end of treatment visit | 3.53 ± 9.002 |
The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.
| Participants | Eltrombopag |
|---|---|
| Rating 0 | 51 |
| Rating 1 | 15 |
| Rating 2 | 10 |
| Rating 3 | 2 |
| Rating 4 | 5 |
| Missing | 22 |
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
| Unit on a scale | Eltrombopag |
|---|---|
| Global Satisfaction change from BL at 12 months | 17.78 ± 29.201 |
| Global Satisfaction change from BL at 24 months | 17.69 ± 26.110 |
| Global Satisfaction change from BL at end of treatment visit | 9.96 ± 33.966 |
| Effectiveness change from BL at 12 months | 18.82 ± 33.809 |
| Effectiveness change from BL at 24 months | 17.99 ± 29.913 |
| Effectiveness change from BL at end of treatment visit | 14.14 ± 36.673 |
| Convenience change from BL at 12 months | 17.69 ± 30.758 |
| Convenience change from BL at 24 months | 19.05 ± 25.189 |
| Convenience change from BL at end of treatment visit | 15.07 ± 30.253 |
| Total score change from BL at 12 months | 54.29 ± 78.218 |
| Total score change from BL at 24 months | 54.72 ± 75.463 |
| Total score change from BL at end of treatment visit | 39.17 ± 86.449 |
On-treatment deaths were reported from the date of first dose of eltrombopag to 30 days after the date of the last non-zero dose of eltrombopag for patients who discontinued on or before month 12 (i.e., non-responders). For patients ongoing at month 12, the on-treatment period lasted until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months), as a patient could restart treatment at any time during study. Post-treatment deaths were collected in the post treatment period from 31 days after last dose of study medication until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months). These are not considered Adverse Events.
| Participants | Eltrombopag |
|---|---|
| On-treatment deaths | 3 |
| Post-treatment deaths | 1 |
| All deaths | 4 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days for patients who discontinued on or before month 12. For patients ongoing at month 12, the on-treatment period lasted until the cut-off date for the primary analysis (22-Oct-2021), up to a maximum of 35 months).Deaths were collected in the post treatment follow up period from 31 days after last dose of study medication until the cut-off date for the primary analysis (22-Oct-2021).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag (On-Treatment) | 3/105 (2.9%) | 21/105 (20%) | 64/105 (61%) |
| Eltrombopag (Post-treatment Follow-up) | 1/102 (1%) | — | — |
| Event | Eltrombopag (On-Treatment) | Eltrombopag (Post-treatment Follow-up) |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/105 | — |
| Intentional product misuseInjury, poisoning and procedural complications | 2/105 | — |
| Platelet count decreasedInvestigations | 2/105 | — |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/105 | — |
| DiarrhoeaGastrointestinal disorders | 1/105 | — |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/105 | — |
| VomitingGastrointestinal disorders | 1/105 | — |
| Cholecystitis acuteHepatobiliary disorders | 1/105 | — |
| Cavernous sinus thrombosisInfections and infestations | 1/105 | — |
| Diarrhoea infectiousInfections and infestations | 1/105 | — |
| Event | Eltrombopag (On-Treatment) | Eltrombopag (Post-treatment Follow-up) |
|---|---|---|
| HeadacheNervous system disorders | 23/105 | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 16/105 | — |
| PetechiaeSkin and subcutaneous tissue disorders | 11/105 | — |
| DiarrhoeaGastrointestinal disorders | 10/105 | — |
| Alanine aminotransferase increasedInvestigations | 9/105 | — |
| NauseaGastrointestinal disorders | 8/105 | — |
| AstheniaGeneral disorders | 8/105 | — |
| AnaemiaBlood and lymphatic system disorders | 7/105 | — |
| Abdominal painGastrointestinal disorders | 7/105 | — |
| Blood alkaline phosphatase increasedInvestigations | 7/105 | — |
| Age, Continuous(Years) | Eltrombopag |
|---|---|
| Mean | 48.1 ± 19.39 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 64 |
| Male | 41 |
| Race (NIH/OMB)(Participants) | Eltrombopag |
|---|---|
| American Indian or Alaska Native | 5 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 95 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Time since initial diagnosis(Days) | Eltrombopag |
|---|---|
| Mean | 366.37 ± 911.420 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2018 to primary completion in Oct 2021, 35 months.
Results were first posted in Dec 2023, 2 years 2 months after primary completion. A results delay was requested in Sep 2022.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →